|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-35S1
|
$75,000
|
$7,500
|
LYNCH, THOMAS
|
YALE UNIVERSITY
|
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-35S2
|
$333,000
|
$33,300
|
LYNCH, THOMAS
|
YALE UNIVERSITY
|
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-35S3
|
$200,000
|
$20,000
|
LYNCH, THOMAS
|
YALE UNIVERSITY
|
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-35S4
|
$150,000
|
$15,000
|
LYNCH, THOMAS
|
YALE UNIVERSITY
|
|
|
Yale Comprehensive Cancer Center Support Grant
|
5P30CA016359-35
|
$2,522,007
|
$252,201
|
LYNCH, THOMAS
|
YALE UNIVERSITY
|
|
|
XLF in double-strand break repair and chemo/radiosensitization
|
5R01CA166264-02
|
$298,958
|
$298,958
|
POVIRK, LAWRENCE
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
|
WU-MDACC Inter-Institutional Molecular Imaging Center
|
5P50CA094056-14
|
$1,264,315
|
$75,859
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-06S1
|
$74,858
|
$6,737
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
|
Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-06
|
$1,560,000
|
$140,400
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
|
Widespread vs Selective Screening for Hepatitis B Infection Prior to Chemotherapy
|
5R21CA167202-02
|
$200,004
|
$200,004
|
HWANG, JESSICA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
Vitamin D Analogs as Adjuvants in Chemotherapy of Cancer
|
5R01CA044722-24
|
$216,873
|
$216,873
|
STUDZINSKI, GEORGE
|
RBHS-NEW JERSEY MEDICAL SCHOOL
|
|
|
Virginia Mason Community Clinical Oncology Program
|
3U10CA035192-29S1
|
$86,403
|
$38,881
|
NICHOLS, CRAIG
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
|
Vindoline and Vinblastine
|
5R01CA115526-09
|
$317,479
|
$317,479
|
BOGER, DALE
|
SCRIPPS RESEARCH INSTITUTE
|
|
|
Validation of prognostic and pathway signatures in lethal prostate cancer
|
5U01CA157703-04
|
$440,421
|
$220,211
|
HALABI, SUSAN
|
DUKE UNIVERSITY
|
|
|
Validation of microRNAs as therapeutic targets in hematological malignancies
|
5R01CA135332-04
|
$306,945
|
$306,945
|
MARCUCCI, GUIDO
|
OHIO STATE UNIVERSITY
|
|
|
Validation of a Novel Treatment for Glioblastoma
|
1R41CA186435-01A1
|
$225,000
|
$112,500
|
KESARI, SANTOSH
|
CURTANA PHARMACEUTICALS, INC.
|
|
|
Validating Syk as a Target for AML Therapy
|
2R01CA140292-06
|
$387,775
|
$387,775
|
STEGMAIER, KIMBERLY
|
DANA-FARBER CANCER INST
|
|
|
Vaccines to promote Tc-1-based targeting of tumor stroma
|
5R01CA140375-05
|
$287,547
|
$143,774
|
STORKUS, WALTER
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
|
Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
|
5P01CA154291-03
|
$3,469,664
|
$346,966
|
BIGNER, DARELL
|
DUKE UNIVERSITY
|
|
|
Vaccine and radiation for the therapy of human cancers
|
ZIA BC 010975
|
$363,542
|
$363,542
|
Hodge, James
|
CCR (NCI)
|
|
|
Vaccine and Drug Combination Therapy for Human Cancers
|
ZIA BC 010661
|
$363,542
|
$181,771
|
Hodge, James
|
CCR (NCI)
|
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-40S1
|
$74,856
|
$3,743
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-40S2
|
$122,401
|
$6,120
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-40S3
|
$150,000
|
$7,500
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
|
UW Comprehensive Cancer Center Support
|
5P30CA014520-40
|
$4,421,130
|
$221,057
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
|
Using Stat3 Signaling Profiles to Understand Chemotherapy Resistance in AML
|
1R01CA175026-01A1
|
$405,847
|
$405,847
|
REDELL, MICHELE
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Using FAP to Selectively Target Epithelial Cancers
|
5R01CA163930-03
|
$325,084
|
$162,542
|
BACHOVCHIN, WILLIAM
|
TUFTS UNIVERSITY BOSTON
|
|
|
Using EMP2 for Image Guided Drug Delivery for Breast Cancer
|
5R01CA163971-03
|
$309,964
|
$309,964
|
WADEHRA, MADHURI
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
Using Diazeniumdiolate Chemistry to Design Nitric Oxide-Based Therapies
|
ZIA BC 005673
|
$528,337
|
$369,836
|
Keefer, Larry
|
CCR (NCI)
|
|
|
Using 18F-EF5 PET to measure hypoxia modulation by Nelfinavir in larynx cancer
|
1R01CA174976-01A1
|
$451,422
|
$451,422
|
MAITY, AMIT
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung Cancer
|
5R01CA172921-02
|
$346,942
|
$173,471
|
ALBELDA, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Use of EF2K Inhibitors to Reduce Toxicity to Normal Tissues in Chemotherapy
|
1R41CA192929-01
|
$222,039
|
$222,039
|
RYAZANOV, ALEXEY
|
LONGEVICA PHARMACEUTICALS, INC.
|
|
|
Use of Beta-lapachone for Lung Cancer Chemotherapy
|
5R01CA102792-12
|
$325,086
|
$325,086
|
BOOTHMAN, DAVID
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-39S1
|
$75,000
|
$6,000
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-39S2
|
$4,154
|
$332
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-39S3
|
$12,487
|
$999
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-39S4
|
$126,993
|
$10,159
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
5P30CA014089-39
|
$6,071,261
|
$485,701
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
Upregulation of Nanog as an Innovative Mechanism for Cancer Drug Resistance.
|
1R21CA178255-01A1
|
$211,410
|
$211,410
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
|
UPRCCC/MDACC: Partnership for Excellence in Cancer Research (1 of 2)
|
3U54CA096300-12S1
|
$84,570
|
$13,531
|
LOPEZ-BERESTEIN, GABRIEL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
UPRCCC/MDACC: Partnership for Excellence in Cancer Research (1 of 2)
|
3U54CA096300-12S2
|
$65,792
|
$10,527
|
LOPEZ-BERESTEIN, GABRIEL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
UPRCCC/MDACC: Partnership for Excellence in Cancer Research (1 of 2)
|
5U54CA096300-12
|
$1,038,286
|
$166,126
|
LOPEZ-BERESTEIN, GABRIEL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
UNMC Eppley Cancer Center Support Grant
|
3P30CA036727-28S1
|
$48,718
|
$2,923
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
|
UNMC Eppley Cancer Center Support Grant
|
5P30CA036727-28
|
$1,485,000
|
$89,100
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
|
Unleashing the Efficacy of PI3K/AKT/mTOR Pathway Inhibitors in B-ALL
|
1F32CA189629-01
|
$53,282
|
$53,282
|
VO, THANH-TRANG
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
|
|
University of Rochester Cancer Center CCOP Research Base
|
3U10CA037420-29S1
|
$365,619
|
$336,369
|
MORROW, GARY
|
UNIVERSITY OF ROCHESTER
|
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-26S1
|
$74,531
|
$6,708
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN
|
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-26S2
|
$49,999
|
$4,500
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN
|
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-26S3
|
$310,728
|
$27,966
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN
|
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
5P30CA046592-26
|
$5,914,688
|
$532,322
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN
|
|
Total relevant funding to Chemotherapy for this search: $278,101,806
|
